Medtronic (NYSE:MDT) Updates FY25 Earnings Guidance

Medtronic (NYSE:MDT - Get Free Report) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share guidance of $5.44-5.50 for the period, compared to the consensus earnings per share estimate of $5.45. Medtronic also updated its FY 2025 guidance to 5.440-5.500 EPS.

Medtronic Trading Down 2.9 %

Shares of NYSE:MDT traded down $2.50 during midday trading on Tuesday, reaching $85.09. The company had a trading volume of 6,798,386 shares, compared to its average volume of 6,246,340. The firm has a market cap of $109.13 billion, a price-to-earnings ratio of 28.72, a price-to-earnings-growth ratio of 2.50 and a beta of 0.84. The company has a fifty day simple moving average of $89.42 and a two-hundred day simple moving average of $84.82. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.61 and a current ratio of 2.13. Medtronic has a 1-year low of $74.66 and a 1-year high of $92.68.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, November 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.25 by $0.01. The company had revenue of $8.40 billion during the quarter, compared to the consensus estimate of $8.27 billion. Medtronic had a net margin of 12.06% and a return on equity of 13.68%. The company's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.25 earnings per share. Research analysts predict that Medtronic will post 5.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

MDT has been the subject of several recent analyst reports. UBS Group upgraded Medtronic from a "sell" rating to a "neutral" rating and increased their target price for the company from $76.00 to $90.00 in a research note on Thursday, August 15th. JPMorgan Chase & Co. decreased their target price on Medtronic from $99.00 to $96.00 and set a "neutral" rating on the stock in a report on Friday. Evercore ISI raised their price objective on shares of Medtronic from $100.00 to $104.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. Wells Fargo & Company increased their target price on Medtronic from $105.00 to $106.00 and gave the company an "overweight" rating in a research note on Wednesday, August 21st. Finally, Daiwa America upgraded Medtronic to a "strong-buy" rating in a report on Friday, August 23rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Medtronic has a consensus rating of "Hold" and a consensus price target of $95.80.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.